NCT05431179 2023-04-21
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
Phase 3 Withdrawn
Oncternal Therapeutics, Inc
CTI BioPharma
Masonic Cancer Center, University of Minnesota
European Organisation for Research and Treatment of Cancer - EORTC